Alexandra (Lisa) H. Filipovich, MD

Ralph J. Stolle Chair, Clinical Immunology

Director, Immune Deficiency and Histiocytosis Program

Medical Director, Diagnostic Immunology Laboratory

Professor, UC Department of Pediatrics

Phone 513-803-3218

Fax 513-803-1969

Email lisa.filipovich@cchmc.org

Clinical Interests

Primary immunodeficiencies; BMT for primary immunodeficiencies; hemophagocytic lymphocytosis; post-BMT immune reconstruction

Lisa Filipovich, MD, began her career at the University of Minnesota where she received her medical degree in 1974 and completed fellowships in both immunopathology and pediatric immunology. She became a professor of pediatrics and served for 10 years as the head of the Division of Immunology at the University of Minnesota Medical School. Dr. Filipovich came to Cincinnati Children’s in 1996. She is currently the Ralph J. Stolle Chair in Clinical Immunology and the director of the Immune Deficiency and Histiocytosis program. She also serves as the medical director of the Diagnostic Immunology Laboratory at Cincinnati Children’s.

Dr. Filipovich has a special interest in histiocytic disorders, especially hemophagocytic lymphohistiocytosis (HLH). Other interests include bone marrow transplant for primary immune deficiencies and post-BMT immune reconstitution. She serves as president of the Histiocyte Society, an international group of more than 200 physicians and scientists who are committed to improving the lives of patients with histiocytosis through research.
MD: University of Minnesota, Minneapolis, MN, 1974.

Residency: University of Minnesota Hospitals, Minneapolis, MN 1975-1978.

Fellowship: Immunopathology, Departments of Pediatrics, Laboratory Medicine and Pathology, University of Minnesota 1978-1979.

Fellowship: Pediatric Immunology, Department of Pediatrics, University of Minnesota 1979-1980.

Certification: Pediatrics, 1980.

Jodele S, Bleesing JJ, Mehta PA, Filipovich AH, Laskin BL, Goebel J, Pinkard SL, Davies SM. Successful early intervention for hyperacute transplant-associated thrombotic microangiopathy following pediatric hematopoietic stem cell transplantation. Pediatr Transplant. 2010 Nov 5.

Marsh RA, Vaughn G, Kim MO, Li D, Jodele S, Joshi S, Mehta PA, Davies SM, Jordan MB, Bleesing JJ, Filipovich AH. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood. 2010 Dec 23;116(26):5824-31.

Marsh RA, Bleesing JJ, Filipovich AH. Using flow cytometry to screen patients for X-linked lymphoproliferative disease due to SAP deficiency and XIAP deficiency. J Immunol Methods. 2010 Oct 31;362(1-2):1-9.

Laskin BL, Goebel J, Davies SM, Khoury JC, Bleesing JJ, Mehta PA, Filipovich AH, Paff ZN, Lawrence JM, Yin HJ, Pinkard SL, Jodele S. Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. Bone Marrow Transplant. 2010 Aug 9.

Filipovich AH, Zhang K, Snow AL, Marsh RA. X-linked lymphoproliferative syndromes: brothers or distant cousins? Blood. 2010 Nov 4;116(18):3398-408.

Marsh RA, Madden L, Kitchen BJ, Mody R, McClimon B, Jordan MB, Bleesing JJ, Zhang K, Filipovich AH. XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood. 2010 Aug 19;116(7):1079-82.

Marsh RA, Satake N, Biroschak J, Jacobs T, Johnson J, Jordan MB, Bleesing JJ, Filipovich AH, Zhang K. STX11 mutations and clinical phenotypes of familial hemophagocytic lymphohistiocytosis in North America. Pediatr Blood Cancer. 2010 Jul 15;55(1):134-40.

Filipovich AH. Hemophagocytic lymphohistiocytosis (HLH) and related disorders. Hematology Am Soc Hematol Educ Program. 2009:127-31.

Nicolaou SA, Neumeier L, Takimoto K, Lee SM, Duncan HJ, Kant SK, Mongey AB, Filipovich AH, Conforti L. Differential calcium signaling and Kv1.3 trafficking to the immunological synapse in systemic lupus erythematosus. Cell Calcium. 2010 Jan;47(1):19-28.

Marsh RA, Villanueva J, Kim MO, Zhang K, Marmer D, Risma KA, Jordan MB, Bleesing JJ, Filipovich AH. Patients with X-linked lymphoproliferative disease due to BIRC4 mutation have normal invariant natural killer T-cell populations. Clin Immunol. 2009 Jul;132(1):116-23.

Gene Therapy for SCID-X1 Using Self-Inactivating Gamma. Principal Investigator. National Institutes of Health. Sep 2010-Aug 2015. #U01 AI 087628.

Rare Diseases Clinical Consortia for the Rare Diseases. Principal Investigator. National Institutes of Health. Sep 2009-Aug 2014. #U54 AI 082973.

Hypoxia and potassium channel activity in T Lymphocytes. Principal Investigator. National Institutes of Health. Jun 2009-Jun 2014. #R01 CA 095286.